15 research outputs found
A phase II study of pemetrexed plus carboplatin as first-line therapy of patients with locally advanced (LA) or metastatic breast cancer (MBC): Preliminary results
No full textRandomized phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing alternative to modified FOLFOX-6 as first-line therapy for colorectal cancer (CRC)
No full textInfluence of tumor control on tumor-related events (TRE) in relapsed ovarian cancer (ROC): Results from OVA-301, a randomized phase III study of trabectedin (Tr) with pegylated liposomal doxorubicin (PLD) versus PLD alone.
No full textFirst-line phase Ib and II studies of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a potential neuropathy-sparing therapy for colorectal cancer (CRC)
No full textTolerability and efficacy of the trifunctional antibody removab<sup>® </sup>(anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study
No full textIrinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study
No full textResponse to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis.
No full textPAM50 intrinsic subtyping and pathologic responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer.
No full text
